GlassScriptPhysician profile
Thomas P Cox
NPI 1235138181
$3,387.17
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $432 · 2020: $121 · 2021: $2,812 · 2022: $21.50.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,807.53 | 2019-2021 | |
| Pfizer INC. | $167.83 | 2019-2020 | |
| Merz North America, INC. | $122.43 | 2019 | |
| Merck Sharp & Dohme LLC | $54.68 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $45.41 | 2019 | |
| Abbvie INC. | $42.88 | 2021-2022 | |
| Novo Nordisk INC | $40.92 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $24.29 | 2019 | |
| Abbott Laboratories | $20.91 | 2019 | |
| Amarin Pharma, INC. | $18.19 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.53 | 2020 | |
| Allergan, INC. | $13.00 | 2019 | |
| Ironshore Pharmaceuticals INC. | $12.57 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Cox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.